Nova Mentis Life Science Corp.
Canadian Securities ExchangeTotal Valuation
Nova Mentis Life Science Corp. carries a market capitalization of 148,319.00, placing it among publicly traded companies globally.
| Market Cap | 148,319.00 |
| Enterprise Value | N/A |
Share Statistics
Nova Mentis Life Science Corp. currently has 29.43M shares outstanding.
| Shares Outstanding | 29.43M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 129.31, and the price-to-book ratio stands at -0.41.
| PE Ratio | N/A |
| PS Ratio | 129.31 |
| PB Ratio | -0.41 |
| P/TBV Ratio | -6.10 |
| P/FCF Ratio | -7.88 |
| P/OCF Ratio | -7.88 |
Financial Position
Nova Mentis Life Science Corp. maintains a current ratio of 0.06, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.06 |
| Quick Ratio | 0.05 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -343.51 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Nova Mentis Life Science Corp.'s stock has declined approximately -96% over the past 52 weeks. The 50-day moving average sits at - -, while the 200-day moving average is - -.
| Beta (5Y) | N/A |
| 52-Week Price Change | -96% |
| 50-Day Moving Average | - - |
| 200-Day Moving Average | - - |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Nova Mentis Life Science Corp. generated 28,346.00 in revenue and converted that into -2.08M in net income, yielding earnings per share of -0.07. EBITDA reached -1.44M, while operating income came in at -1.44M.
| Revenue | 28,346.00 |
| Gross Profit | 28,346.00 |
| Operating Income | -1.44M |
| Pretax Income | -2.08M |
| Net Income | -2.08M |
| EBITDA | -1.44M |
| EBIT | -1.44M |
| Earnings Per Share (EPS) | -0.07 |
Balance Sheet
Total book value stands at -8.89M, with working capital of -613,161.00 providing operational flexibility.
| Cash & Cash Equivalents | 24,441.00 |
| Total Debt | N/A |
| Net Debt | -24,441.00 |
| Equity (Book Value) | -8.89M |
| Book Value Per Share | -0.30 |
| Working Capital | -613,161.00 |
Cash Flow
Nova Mentis Life Science Corp. produced -465,009.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | -465,009.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | -465,009.00 |
| FCF Per Share | -0.02 |
Margins
Nova Mentis Life Science Corp. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -5,090.78 and net profit margin of -7,352.31 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -5,090.78 |
| Pretax Margin | -7,352.31 |
| Profit Margin | -7,352.31 |
| EBITDA Margin | -5,079.65 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.75 |
| FCF Yield | -12.69 |
Stock Splits
Nova Mentis Life Science Corp.'s most recent stock split took place on June 26, 2020 with a 4:1 split ratio.
| Last Split Date | 6/26/2020 |
| Split Ratio | 4:1 |
Scores
Nova Mentis Life Science Corp. posts an Altman Z-Score of -1,633.04, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -1,633.04 |